Figure 4—Time-dependent incidence of subjects experiencing treatment-emergent nausea (ITT population).Table 1 —Most frequent adverse events with incidence >10% in any treatment arm (ITT)* Preferred term Placebo 5 /H9262g exenatide 10 /H9262g exenatide n 247 245 241 Nausea 51 (20.6) 96 (39.2) 117 (48.5) Hypoglycemia 31 (12.6) 47 (19.2) 67 (27.8) Upper respiratory tract infection 48 (19.4) 28 (11.4) 42 (17.4) Vomiting 11 (4.5) 36 (14.7) 33 (13.7) Diarrhea 16 (6.5) 25 (10.2) 42 (17.4) Feeling jittery 17 (6.9) 21 (8.6) 28 (11.6) Headache 12 (4.9) 27 (11.0) 18 (7.5) Data are n(%). *Treatment emergent.Kendall and Associates DIABETES CARE,VOLUME 28, NUMBER 5, M AY2005 1089